The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Other Relationship - I am an employee of Partnership for Health Analytic Research, LLC, a health services research company paid by Celgene to conduct this research.; I am an employee of Partnership for Health Analytic Research, LLC, a health services research company paid for previous researches by AbbVie, Amgen, BMS, Boston Scientific, Celgene, CR Bard, EISAI, Eli Lilly, Ethicon, Genentech, Ipsen, Janssen, Jazz, Kit
The use of real-world data to examine comparative effectiveness research (CER) and treatment patterns in HER2-negative and triple-negative metastatic breast cancer (MBC): A systematic literature review.
 
Monika Parisi
Employment - Celgene
Stock and Other Ownership Interests - Celgene
 
Corey Pelletier
Employment - Celgene; Eisai
Stock and Other Ownership Interests - Celgene
 
Dasha Cherepanov
No Relationships to Disclose
 
Michael S Broder
Research Funding - Amgen (Inst)
Travel, Accommodations, Expenses - Genentech; Novartis
Other Relationship - Amgen; Bard Medical; Boston Scientific; Bristol-Myers Squibb; Celgene; Eisai; Genentech; Genomic Health; Helsinn Healthcare; Ipsen; Jazz Pharmaceuticals; Johnson & Johnson; Lilly; Novartis; Onconova Therapeutics; Otsuka; Shionogi
 
Nadia Noormohamed
Employment - Bayer (I)